IP Library Granted Patent US 12,060,583
Granted Patent B2
US 12,060,583 · App. 17/046,871 · Granted Aug 13, 2024

Scalable chromatography process for purification of human cytomegalovirus

Inventors: Adam Kristopeit (Lansdale, PA); Janelle Konietzko (Lansdale, PA); Wanli Ma (Lansdale, PA); Katherine Phillips (Audubon, PA); Andrew Swartz (Chalfont, PA); Sheng-Ching Wang (Eagleville, PA); Marc D. Wenger (Allentown, PA); Matthew Woodling (Lansdale, PA); Tiago Matos (Philadelphia, PA)
Assignee: Merck Sharp & Dohme LLC
C12N7/02B01D15/362B01D15/363C12N5/0621C12N2710/16111
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,583
App. No.
17/046,871
Granted
Aug 13, 2024
Kind
B2
Abstract

The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.

Claims (13)

1. A method for the purification of HCMV from a cell culture medium comprising the steps of:

a) harvesting cell culture medium from a culture of ARPE-19 cells infected with HCMV;

b) subjecting the cell culture medium to nuclease treatment using an endonuclease at a concentration of 10-160 U/mL;

c) clarifying the nuclease-treated cell culture medium using a 1.2 μm glass fiber filter to obtain a clarified cell culture medium;

d) contacting the clarified cell culture medium comprising HCMV with an anion exchange chromatography membrane under conditions that allow the HCMV to bind to the anion exchange chromatography membrane and then eluting the HCMV from the anion exchange chromatography membrane to obtain an eluate;

e) contacting the eluate with a mixed-mode chromatography resin which is a hydrophobic anion exchange chromatography resin having a molecular weight exclusion of about 700 kDa and then collecting the HCMV from the mixed mode chromatography resin to obtain purified HCMV; and

f) performing tangential flow filtration on the purified HCMV collected from step e) to adjust to the desired concentration and buffer

wherein the cells are grown on microcarriers;

wherein the purified HCMV has at least 80% HCMV protein purity and/or a process yield of at least 40%; and

wherein the HCMV is a recombinant genetically modified HCMV having a genomic sequence of SEQ ID NO: 1.

2. The method of claim 1 , wherein step b) is run prior to step a) by addition of nuclease to the cell culture medium prior to harvesting.

3. The method of claim 1 , wherein step b) is run following step a).

4. The method of claim 1 , wherein the purified HCMV contains 10 ng or less hcDNA per dose.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME LISTED INCORRECTLY KATIE PHILLIPS SHOULD BE LISTED AS KATHERINE PHILLIPS AND THE INVENTORS EXECUTION DATES WERE LISTED INCORRECTLY, PREVIOUSLY RECORDED ON REEL 054027 FRAME 430. PREVIOUSLY RECORDED ON REEL 54027 FRAME 430. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 9, 2024
From: KRISTOPEIT, ADAM; KONIETZKO, JANELLE; MA, WANLI; PHILLIPS, KATHERINE; SWARTZ, ANDREW; WANG, SHENG-CHING; WENGER, MARC D.; WOODLING, MATTHEW; MATOS, TIAGO
To: MERCK SHARP & DOHME LLC
Reel/Frame 068533/0607 →
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: KRISTOPEIT, ADAM; KONIETZKO, JANELLE; MA, WANLI; PHILLIPS, KATIE; SWARTZ, ANDREW; WANG, SHENG-CHING; WENGER, MARC D.; WOODLING, MATTHEW; MATOS, TIAGO
To: MERCK SHARP & DOHME CORP.
Reel/Frame 054027/0430 →